TC
KURA icon

Telemus Capital’s Kura Oncology KURA Stock Holding History

Telemus Capital’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,000
Closed -$682K – 409
2020
Q3 		$682K Hold
20,000
– – 0.05% 255
2020
Q2 		$357K Buy
20,000
+10,000
+100% +$144K 0.03% 318
2020
Q1 		$171K Buy
+10,000
New +$114K 0.01% 361

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Telemus Capital's KURA Position: Q4 2020 in Review

Telemus Capital sold out of Kura Oncology (KURA) in Q4 2020, closing a stake of 20,000 shares — an estimated $682K sold.

Telemus Capital first reported a position in KURA in Q1 2020 and held it in 3 quarters. The position peaked at $682K in Q3 2020. 198 funds tracked by Wall St. Rank hold KURA as of Q4 2020.

  • Telemus Capital reported no remaining Kura Oncology position as of Q4 2020 after selling out during the quarter.
  • Telemus Capital sold 20,000 Kura Oncology shares in Q4 2020, an estimated $682K.
  • Telemus Capital first reported a position in Kura Oncology in Q1 2020 and held it in 3 quarters.
  • Telemus Capital's Kura Oncology position peaked at $682K in Q3 2020.
  • 198 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2020.

Based on Telemus Capital's 13F filing for Q4 2020, filed 28 Jan 2021.